Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Featured Clinical Focus
Clinical Focus
News
Conferences
Media
Publications
Resources
Subscribe
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Featured Clinical Focus
  • AML
  • Biomarker-Driven Lung Cancer
  • Breast Cancer
  • CAR T-Cell Therapy
  • Chronic Lymphocytic Leukemia
  • EGFR+ Lung Cancer
  • Follicular Lymphoma
  • GI Cancers
  • HCC
  • HER2-Positive Breast Cancer
  • Lung Cancer
  • Lymphomas
  • Mantle Cell Lymphoma
  • MPNs
  • Multiple Myeloma
  • Prostate Cancer
  • Renal Cell Carcinoma
  • Thyroid Cancers
Clinical FocusSee All >
  • Brain Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancers
  • Hematology
  • Leukemias
  • Lung Cancer
  • Lymphomas
  • Melanoma
  • Sarcoma
  • Skin Cancers
  • Thyroid Cancers
baltimore conference logo
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Evaluating Next Steps for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

September 21, 2020
Robert L. Coleman, MD
Robert L. Coleman, MD

Conference | ESMO Congress

Robert L. Coleman, MD, discusses the next steps for tisotumab vedotin following the presentation of findings from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study in patients with previously treated recurrent or metastatic cervical cancer.

Robert L. Coleman, MD, chief scientific officer, The US Oncology Network, discusses the next steps for tisotumab vedotin following the presentation of findings from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study in patients with previously treated recurrent or metastatic cervical cancer.

This study met its primary end point of objective response rate, which was clinically and significantly improved. Based on this, Coleman says the next step would be to pursue regulatory action, such as an accelerated approval from the FDA. Another next step would be to develop a phase 3 study to evaluate this agent against chemotherapy.

Coleman says an important next step, considering the positive single-agent activity observed in the study, would be to see what tisotumab vedotin could be combined with to improve outcomes further. A number of studies are now ongoing, evaluating potential combinations, such as with immunotherapy or anti-angiogenesis therapy, as well as in different lines and different schedules. This will help to expand our knowledge of the best dosing frequency.